MOLECULAR DIAGNOSTIC TEST FOR CANCER

• Main Authors: MICHIE CAROLINE, BYLESJO MAX, MCCAVIGAN ANDRENA, HARKIN DENNIS PAUL, DAVISON TIMOTHY, HILL LAURA A, WINTER ANDREAS, DEHARO STEVE, TRINDER CLAIRE, KEATING KATHERINE E, PROUTSKI VITALI, PATTERSON FIONNUALA, O'DONNELL JUDE, KENNEDY RICHARD, O'BRIEN EAMONN J, GOURLEY CHARLIE
• Format: Patent
• Language: English; Korean
• Published: 14.04.2014
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that are responsive to anti-angiogenesis therapeutics and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.